INTERNATIONAL PATENT: ASTRAZENECA AB FILES APPLICATION FOR "BISPECIFIC T-CELL ENGAGER MOLECULE COMBINATIONS FOR USE IN TREATMENT OF CLAUDIN18.2 EXPRESSING SOLID TUMORS"

GENEVA, May 11 -- ASTRAZENECA AB (SE-151-85 Sodertalje) filed a patent application (PCT/IB2025/061171) for "BISPECIFIC T-CELL ENGAGER MOLECULE COMBINATIONS FOR USE IN TREATMENT OF CLAUDIN18.2 EXPRESSING SOLID TUMORS" on Nov 03, 2025. With publication no. WO/2026/094002, the details related to the patent application was published on May 07, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): NATOLI, Marina (c/o ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue,Cambridge Biomedical CampusCambridge CB2 0AA), RAHMY, Sharif (c/o MEDIMMUNE, LLCOne MedImmune WayGaithersburg, Maryland 20878)

Abstract: Pro...